Looking back at the performance of ARK Invest, led by Cathie Wood (“Cathie Wood”), in 2025, despite reducing its holdings of Tesla (TSLA) by over 633,000 shares during the period, the company still firmly held the position of ARK Invest’s largest holding. The overall performance of its funds also significantly outperformed major U.S. benchmark indices.
ARK Invest has demonstrated a clear strategic shift in its investment focus for 2026, significantly leaning toward early-stage biotech and genomics while gradually reducing some holdings in consumer tech, diagnostics, and space technology.
The core of this strategic adjustment is a substantial increase in holdings related to gene editing and genomics. The flagship fund ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) collectively purchased over 195,000 shares of the U.S. biotech company Beam Therapeutics (BEAM). As a pioneer in base editing technology, BEAM is dedicated to developing precise genetic medicines to correct disease-causing mutations. This move has pushed its holding value to approximately $5.4 billion, making it one of ARK’s most aggressive investment bets in recent times.
ARK’s increase in holdings is continuous, extending its previous pattern of adding shares in Intellia Therapeutics (NTLA) with another purchase of approximately 236,000 shares. The company utilizes CRISPR technology to repair disease-causing genes, aligning closely with ARK’s investment direction. To further solidify its position in the fields of genomic discovery and precision medicine tools, ARK also simultaneously purchased over 423,000 shares of sequencing technology provider Pacific Biosciences of California (PACB). Additionally, ARK invested over $3 million to increase its holdings in Twist Bioscience (TWST), which focuses on synthetic DNA research and development, by 101,000 shares, and acquired 88,000 shares of Personalis (PSNL), a company developing ultra-deep DNA sequencing technology for early cancer detection.
While actively deploying capital, ARK has also systematically adjusted some of its existing holdings. In the healthcare sector, the ARK Genomic Revolution ETF (ARKG) reduced its holdings in Ionis Pharmaceuticals (IONS), which focuses on RNA-targeted therapies, and simultaneously scaled back its positions in genetic testing company Natera (NTRA) and cancer detection firm Guardant Health (GH).
In consumer tech and other areas, the flagship fund ARK Innovation ETF (ARKK) completed a structural portfolio adjustment by selling over 72,000 shares of streaming platform Roku (ROKU) and reducing its holdings in Canadian e-commerce software provider Shopify (SHOP) by more than 29,000 shares.
